

CorMedix Inc.
Form 4
June 22, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Pfaffle Antony

(Last) (First) (Middle)

C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200

(Street)

BEDMINSTER, NJ 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [CRMD]

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
Interim Chief Medical Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|--------------------------------------|--|--------------------------------|---|---|--|---|
| Common Stock, \$0.001 par value per share | 06/20/2016 | | M | 10,000 | A \$ 0.68 10,000 | D | |
| Common Stock, \$0.001 par value per share | 06/20/2016 | | S | 5,000 | D \$ 2.1713 5,000 | D | |
| Common Stock, | 06/20/2016 | | S | 5,000 | D \$ 0 2.1424 | D | |

Edgar Filing: CorMedix Inc. - Form 4

| | | | | | | | |
|---|------------|---|--------|---|------------------|--------|---|
| \$0.001 par value per share | | | | | (2) | | |
| Common Stock, \$0.001 par value per share | 06/21/2016 | M | 19,657 | A | \$ 0.68 | 19,657 | D |
| Common Stock, \$0.001 par value per share | 06/21/2016 | S | 9,657 | D | \$ 2.1208 (3) | 10,000 | D |
| Common Stock, \$0.001 par value per share | 06/21/2016 | S | 7,181 | D | \$ 2.113 (4) | 2,819 | D |
| Common Stock, \$0.001 par value per share | 06/21/2016 | S | 2,000 | D | \$ 2.1529 (5) | 819 | D |
| Common Stock, \$0.001 par value per share | 06/21/2016 | S | 819 | D | \$ 2.2122 (6) | 0 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------|----------------------------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |

Edgar Filing: CorMedix Inc. - Form 4

| | | | | | | | | | |
|-----------------------------|----------|------------|--|---|--------|-------------|------------|---|---------|
| Stock Option (right to buy) | \$ 2.27 | | | | | <u>(7)</u> | 04/01/2024 | Common Stock, \$0.001 par value per share | 100,000 |
| Stock Option (right to buy) | \$ 2.02 | | | | | <u>(8)</u> | 01/09/2024 | Common Stock, \$0.001 par value per share | 100,000 |
| Stock Option (right to buy) | \$ 2.02 | | | | | <u>(9)</u> | 01/09/2024 | Common Stock, \$0.001 par value per share | 30,000 |
| Stock Option (right to buy) | \$ 0.9 | | | | | <u>(10)</u> | 03/22/2023 | Common Stock, \$0.001 par value per share | 210,000 |
| Stock Option (right to buy) | \$ 0.68 | 06/20/2016 | | M | 10,000 | <u>(11)</u> | 12/05/2022 | Common Stock, \$0.001 par value per share | 10,000 |
| Stock Option (right to buy) | \$ 0.68 | 06/21/2016 | | M | 19,657 | <u>(11)</u> | 12/05/2022 | Common Stock, \$0.001 par value per share | 19,657 |
| Stock Option (right to buy) | \$ 2.1 | | | | | <u>(12)</u> | 01/14/2021 | Common Stock, \$0.001 par value per share | 30,000 |
| Stock Option (right to buy) | \$ 3.125 | | | | | <u>(13)</u> | 03/30/2020 | Common Stock, \$0.001 par value per share | 20,000 |
| Stock Option (right to buy) | \$ 5 | | | | | <u>(14)</u> | 02/24/2025 | Common Stock, \$0.001 par value per share | 75,000 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Pfaffle Antony C/O CORMEDIX INC. 1430 U.S. HIGHWAY 206, SUITE 200 BEDMINSTER, NJ 07921 | X | | Interim Chief Medical Officer | |

Signatures

Alexander M. Donaldson, with a Power of Attorney for Antony E. Pfaffle,
M.D. 06/22/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.16 to \$2.19, inclusive.
 - (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.13 to \$2.19, inclusive.
 - (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.11 to \$2.13, inclusive.
 - (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.10 to \$2.13, inclusive.
 - (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.15 to \$2.17, inclusive.
 - (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.20 to \$2.22, inclusive.
 - (7) The options vested 100% on April 2, 2014.
 - (8) The options vested 100% on January 10, 2014.
 - (9) The options vest in full on the first anniversary of the date of grant.
 - (10) These options vest based on performance milestones running through December 31, 2014.
 - (11) These options vested as follows: (a) fifty percent (50%) on the date of the issuance of the CE mark certification, which occurred on July 5th, 2013, and (b) fifty percent (50%) on December 31, 2013.
 - (12) These options vested on January 14, 2012.
 - (13) These options vested as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.
 - (14) These options were granted on February 24, 2015, and vested immediately.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.